Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00312338 · ClinicalTrials.gov registry record · Phase 4
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
NCT00312338: Completed Phase 4 study, sponsored by Alcon Research.
NCT00312338 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 137 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00312338, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
Study Summary
Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora
Primary Outcome
Susceptibility change refers to a change in vulnerability of a specified bacterial strain to antibiotic treatment. Susceptibility was assessed by broth microdilution methods recommended by the Clinical and Laboratory Standards Institute (CLSI). 0% = zero isolates were resistant to antibiotic 100% = all isolates were resistant to antibiotic
Interventions
- DRUG VIGAMOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2006-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
What the finished NCT00312338 record still lists
NCT00312338 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which VIGAMOX is the first listed.
NCT00312338 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00312338 about?
NCT00312338 is a clinical study titled "Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora". Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora
What is the current status of trial NCT00312338?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2006-06. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00312338?
The interventions under investigation include: VIGAMOX (DRUG).
Who is sponsoring clinical trial NCT00312338?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00312338's enrollment target sits among peer trials
137 594th of 2000 higher than 1,405 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia